Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by dysregulated innate and adaptive immunity, high‑titer autoantibodies, immune complex deposition, complement activation, and multi‑organ damage. Within the innate compartment, monocytes and macrophages exhibit altered differentiation, transcriptional programs, effector functions, and metabolic states that collectively sustain inflammation and impair resolution.

Understanding the intricate and dysfunctional behavior of macrophages in SLE is paramount for developing next-generation therapeutics. At Creative Biolabs, we provide a comprehensive, end-to-end research platform to dissect macrophage biology in lupus, from quantifying fundamental defects in vitro to validating novel macrophage-targeting drugs in advanced pre-clinical models.

The Roles of Macrophages in SLC

Abnormalities in cell death have been demonstrated in patients with SLE, including enhanced apoptosis, necrosis, and autophagy. Macrophages from SLE patients show defects in the clearance of apoptotic cells (ACs). The ACs uncleared efficiently may release autoantigens and activate the autoreactive B cells, resulting in loss of tolerance to autoantigens as well as production of autoantibodies. Then the resultant immune complex (IC) deposition causes tissue injuries in different organs affected. In addition, Type I interferon (IFN) can induce plasma cells to produce more autoantibodies and inhibit the clearance of ACs by macrophages. Moreover, macrophages have well-developed secretory functions and serve as an important source for a variety of cytokines, by which macrophages participate in inflammation and the modulation of adaptive immunity.

Fig.1 Possible mechanism of macrophage polarization in SLE.¹

Polarization of Macrophages in SLE

Macrophages can be classified as, but not limited to, classically-activated M1 (infiltrating and inflammatory) macrophages and alternatively-activated M2 (tissue-resident and trophic) macrophages. Studies have shown different functions for M1 and M2 macrophages in SLE. The process of monocyte-to-macrophage differentiation contributes to SLE pathogenesis, possibly by polarizing macrophages towards classic M1 activation. M1 macrophages promote tissue damage, while M2 macrophages participate in tissue healing in SLE. Adoptive transplantation of M2, but not M1 macrophages significantly ameliorated SLE disease activity.

Type I Interferon and Macrophage Function

Type I IFN has been considered as the central pathogenic cytokine in SLE development. Plasmacytoid dendritic cells (pDCs) are capable of producing massive amounts of type I IFNs upon stimulation. Furthermore, TREM-like transcript 4 (TREML4) may potentiate toll-like receptor 7 (TLR7) signaling and type I IFN production in macrophages. Type I IFNs can induce the formation of neutrophil extracellular traps, which are a source of self-stimuli and reciprocally enhance the production of type I IFNs. Type I IFN can induce plasma cells to produce more autoantibodies and inhibit the clearance of ACs by macrophages.

Creative Biolabs Macrophage Platforms for SLE Research

Dissecting the complex roles of macrophages in SLE requires a sophisticated, multi-modal platform. We have developed a comprehensive suite of high-end in vitro assays, advanced in vivo models, and cutting-edge analytical services specifically tailored to interrogate macrophage-driven pathology in SLE. We empower our clients to validate novel targets, screen therapeutic candidates, and understand their mechanism of action with unparalleled depth.

Primary Cells & Differentiation

• Human monocytes → M‑CSF/GM‑CSF–derived macrophages; optional polarization (IFN‑γ/LPS; IL‑4/IL‑13; IL‑10; TGF‑β; ICs; IFN‑I).
• Tissue‑mimetic macrophages: Kidney‑like (tubular epithelium‑conditioned), skin‑like (keratinocyte‑conditioned), microglia‑like (CSF1/IL‑34/TGF‑β); optional matrix and hypoxia conditioning.
• Donor diversity panels: Age/sex/ethnicity‑balanced cohorts; SLE patient‑derived monocytes.

Co‑Culture & Organ‑Relevant Systems

• Kidney: Macrophage–podocyte–mesangial–tubular epithelial tri/quad‑cultures; IC deposition models; transwell albumin flux; fibrosis endpoints.
• Skin: Macrophage–keratinocyte–fibroblast models; UV‑induced damage; cutaneous cytokine loops.
• CNS: Microglia‑like macrophages with neurons/astrocytes; synaptosome phagocytosis; myelin debris clearance.
• Endothelium/Vasculature: TEM under flow; oxLDL uptake; efferocytosis in plaque‑like matrices.
• Pregnancy‑mimetic: Decidual stromal cells/trophoblast co‑cultures to study tolerance cues.

Functional Assays

• Phagocytosis: pHrodo‑apoptotic cell uptake; MerTK/AXL dependency; LAP markers.
• FcγR Signaling: IgG IC stimulation; SYK/BTK phosphorylation; transcriptional outputs; FcγRIIb rescue experiments.
• Complement Readouts: C3b/iC3b opsonization; C3a/C5a chemotaxis; CR3/CR4 functional assays.
• Inflammasome & Cell Death: NLRP3 activation (ASC specks, IL‑1β release); pyroptosis/necrosis assays.
• Antigen Presentation: MHC‑II upregulation, peptide‑MHC tetramers; T cell activation/proliferation (CFSE/CTV).
• Cytokine/Chemokine Panels: Multiplex Luminex/ELISA for TNF‑α, IL‑6, IL‑10, IL‑1β, CXCL9/10, CCL2.
• Migration/Chemotaxis: Transwell, under‑flow microfluidics; CCL2/C5a gradients.

How to Get Started

Contact Creative Biolabs to co‑design a macrophage program tailored to your SLE biology.

Therapeutic Targeting of Macrophages in SLE

SLE is characterized by widespread inflammation in connective tissues, and it has no known cure. As a result of the important and deterministic roles in both health and disease, macrophages have gained considerable attention for therapy of SLE.

• Blocking recruitment of monocytes and macrophage activation by targeting the colony-stimulating factor (CSF-1)/CSF-1 receptor signaling axis, C-X-C motif chemokine receptor 9 (CXCR9), and Bruton's tyrosine kinase.
• Modulation of macrophages. 1) Induction of M2 macrophage polarization and the production of anti-inflammatory cytokines by pioglitazone, the aryl hydrocarbon receptor (AhR)-mediated signaling pathway and expression of peroxisome proliferators-activated receptors (PPARγ); 2) inhibition of M1 inflammatory phenotypes in vitro by sodium valproate, a histone deacetylase (HDAC) inhibitor.
• Promoting clearance of ACs by macrophages via PPARs and liver X receptors.

Our Assays: Advancing SLE Macrophage Research

We provide robust, cell-based assay systems that model the key functional dysfunctions of SLE macrophages.

Our expertise includes:

• Validating macrophage-specific targets.
• Screening compounds that restore macrophage homeostasis.
• Defining the mechanism of action for novel immunomodulators.
• Providing the critical pre-clinical data package for your IND filing.

Contact our scientific team today to discuss your SLE research and discover how our specialized macrophage platform can accelerate your program.

Related Products

Contact us for the latest catalog and custom options.

Scientific Resources

Q & A

Q: Which macrophage source best models lupus nephritis?

A: Human monocyte‑derived macrophages conditioned with kidney epithelial factors under hypoxia model the interstitial niche; coupling with IgG ICs and C5a recapitulates LN triggers.

Q: Which readouts differentiate pro-resolving vs pro-inflammatory macrophages?

A: MerTK/AXL/TREM2, lipid mediator profiles, IL-10 vs TNF/IL-6 balance, mitochondrial respiration indices.

Q: How do you evaluate macrophage contribution to fibrosis in lupus nephritis?

A: We monitor TGF-β/PDGF signaling, collagen gene expression, and fibroblast activation markers in macrophage-fibroblast co-cultures, combined with 3D matrix remodeling assays.

Q: Can you test the efficacy of small-molecule inhibitors or biologics on macrophage function?

A: Yes. We conduct dose-response analyses on cytokine release, phagocytosis, efferocytosis, and signaling readouts to determine EC50/IC50 profiles and mechanism of action.

Q: What are typical timelines?

A: Cell studies often complete in 4–8 weeks depending on donor count and analytics depth; multi‑omics adds time for sequencing and analysis.

Design the right macrophage model for your SLE program. Speak with our immunology experts to align mechanism, biomarkers, and decision‑making—from hypothesis to preclinical proof‑of‑concept.

Start your SLE macrophage project with Creative Biolabs today.

Reference

1. Ahamada, Mariame Mohamed, Yang Jia, and Xiaochuan Wu. "Macrophage polarization and plasticity in systemic lupus erythematosus." Frontiers in immunology 12 (2021): 734008. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.734008